Correction to: Association of day-of-injury plasma glial ﬁbrillary acidic protein concentration and six-month posttraumatic stress disorder in patients with mild traumatic brain injury

Neuropsychopharmacology, 2022 · DOI: https://doi.org/10.1038/s41386-022-01466-3 · Published: September 30, 2022

Simple Explanation

This is a correction to a previously published article regarding the measurement of GFAP (glial fibrillary acidic protein) in patients with mild traumatic brain injury. The original article incorrectly stated that GFAP was measured in serum, when it was actually measured in plasma. The correction clarifies that all samples in the study were measured in plasma, as GFAP can be measured in either serum or plasma. The title of the article was also updated to reflect this change. The authors state that this correction does not affect any of the data or the scientific conclusions of the paper. The original article has been updated with this correction.

Study Duration

Not specified

Participants

Patients with mild traumatic brain injury

Evidence Level

Not specified

Key Findings

1
The primary finding is a correction of the material measured; GFAP was measured in plasma, not serum, in the original study.
2
The clarification regarding plasma versus serum measurement of GFAP does not change the data or scientific conclusions of the original paper.
3
The title of the original article has been updated to reflect the correction, specifying plasma GFAP.

Research Summary

This article is a correction to a previously published study concerning the association of GFAP concentration and posttraumatic stress disorder in patients with mild traumatic brain injury. The correction clarifies that GFAP was measured in plasma, not serum, and the title of the article has been updated accordingly. The authors emphasize that this correction does not alter the original data or the scientific conclusions of the study.

Practical Implications

Accuracy in Research

Highlights the importance of accurate reporting of methodologies, especially regarding biological sample types.

Data Integrity

Reassures readers that the study's findings remain valid despite the correction.

Transparency

Demonstrates the commitment to transparency and accuracy in scientific publications.

Study Limitations

1
The correction itself does not present new limitations but addresses a previous inaccuracy.
2
The limitations of the original study still apply.
3
This is only a correction, it does not expand on the research.

Your Feedback

Was this summary helpful?

Back to Pharmacology